更新于：2024-06-20

Chlorhexidine Hydrochloride

盐酸氯己定

更新于：2024-06-20

概要

概要

基本信息

药物类型

小分子化药

别名

Chlorhexidine hydrochloride (JP17/USP)、CHX、洗必泰

+ [1]

靶点-

作用机制

细胞膜功能抑制剂

治疗领域-

在研适应症-

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

结构

分子式C22H31Cl3N10

InChIKeyAVRXPIQGQAHQTQ-UHFFFAOYSA-N

CAS号3697-42-5

关联

547

项与盐酸氯己定相关的临床试验

IRCT20240221061066N1 / Suspended临床4期IIT

Investigation of antimicrobial effect of green tea and chlorhexidine mouthwashes on the frequency of Streptococcus mutans strains in children with removable orthodontic appliances: a randomized clinical trial study

开始日期2024-09-22

申办/合作机构-

CTRI/2024/05/067879 / Not yet recruiting临床3期

A Comparative Evaluation for the efficacy of Chlorhexidine Gel AndKhadir (Acacia catechu) Gel as an adjunct to Scaling & Root Planing, in Chronic Periodontitis cases: A clinical study - NIL

开始日期2024-07-20

申办/合作机构-

CTRI/2024/05/067738 / Not yet recruiting临床2期

A single blind, single centric, randomized 3 arm parallel study to demonstrate the efficacy and tolerability of Gurunanda Natural Oil Pulling Oral Rinse in the management of Gum Health and Gingivitis when compared to Chlorhexidine and Placebo. - NIL

开始日期2024-06-24

申办/合作机构

GuruNanda LLC初创企业

100 项与盐酸氯己定相关的临床结果

登录后查看更多信息

100 项与盐酸氯己定相关的转化医学

登录后查看更多信息

100 项与盐酸氯己定相关的专利（医药）

登录后查看更多信息

9,668

项与盐酸氯己定相关的文献（医药）

2024-06-01·Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

BD Chloraprep™ (“2 % chlorhexidine with 70 % isopropyl alcohol”) versus povidone iodine plus alcohol, for prevention of blood culture contamination at children: An investigator-initiated, open-label, single centre, randomized controlled trial

Article

作者: Şahinkaya, Şahika ; Devrim, İlker ; Sözen, Ceren ; Kaçar, Pelin ; Yaman, Yakup ; Ayhan, Fahri Yüce ; Yılmaz Çelebi, Miray ; Bayram, Süleyman Nuri ; Cem, Ela

INTRODUCTION:

One of the important problems that lower the diagnostic value of blood culture is contamination with skin organisms. The povidone-iodine, alcohol, and chlorhexidine gluconate alcohol are used for disinfection prior to blood sampling for culture.

METHODS:

The investigator-initiated, open label, single centre, randomised trial compared blood culture contamination rates between two groups of patients in which using a povidone iodine skin-preparation process with the contamination rate for using "2 % chlorhexidine with 70 % isopropyl alcohol" skin-disinfection. The patients who required sampling for blood cultures were included in the study and study period was from 15 March 2023 to 15 July 2023.

RESULTS:

A total of 400 blood cultures were obtained during the study, including 133 in the study group and 267 in the control group. In the total blood cultures, 11.75 % (n = 47) had microorganism isolation. Among them 39 (9.75 %) were contaminants and 8 (2 %) of them were true pathogens. The contaminant microorganisms were as following; 34 coagulase-negative Staphylococci, 3 Micrococcus spp, and 2 Streptococci viridans. The blood culture contamination rate in the study group was 5.3 % (n = 7) and 12.0 % (n = 32) in the control group, and significantly lower in the study group (p = 0.033). There is no significant difference regarding skin related side effects between two groups.

CONCLUSIONS:

This study, showed that 2 % chlorhexidine gluconate in 70 % isopropyl alcohol is more efficacious in children than 10 % povidone-iodine preparations for disinfecting the skin prior to blood specimen collection for prevention of blood culture contamination.

2024-05-01·Microscopy research and technique

Morphological changes and viability of Streptococcus mutans biofilm treated with erythrosine: A confocal laser scanning microscopy analysis

Article

作者: Duarte, Simone ; Gonçalves, Letícia Machado ; Andrade-Maia, Gabriele ; Paschoal, Marco Aurélio Benini ; Cavalcante, Salma Ivanna Araújo

Abstract:

Antimicrobial photodynamic therapy (a‐PDT) is a modality that aims to induce microorganisms through visible light, a photosensitizer, and molecular oxygen. This therapy has shown promising results in controlling cariogenic biofilm in vitro and in vivo counterparts. This study investigated bacterial viability and morphological characterization of Streptococcus mutans mature biofilms after combination of erythrosine and a high potency dental curing light. Biofilms were formed on saliva‐coated hydroxyapatite disks in batch culture. The samples were performed in triplicates. Fresh medium was replaced daily for five days and treated using 40 μM of E activated by HL 288 J/cm2 and total dose of 226 J at 1200 mW/cm2. Phosphate buffer saline and 0.12% of chlorhexidine were used as negative and positive control, respectively. After treatment, biofilms were assessed for microbial viability and morphological characterization by means of bio‐volume and thickness. COMSTAT software was used for image analysis. Data were analyzed using two‐way ANOVA followed by Tukey test with significance level 5%. The application of a‐PDT and CHX treatments decreased S. mutans bacterial viability. The image analysis showed more red cells on biofilms when compared to other groups, demonstrating photobacterial killing. Erythrosine irradiated with a high potency curing light can potentially act as an antimicrobial tool in the treatment of cariogenic biofilms. The morphology and viability of microorganisms were impacted after treatment. Treatment with photodynamic therapy may be able to reduce the bio‐volume and viability of bacteria present in biofilms.

Clinical Relevance and Research Highlights:

The use of the a‐PDT technique has been applied in dentistry with satisfactory results. Some applications of this technique are in stomatology and endodontics. In the present study, we sought to understand the use of photodynamic therapy in the control of biofilm and the results found are compatible with the objective of microbiological control proposed by this technique, thus raising the alert for future studies in vivo using the combination of a‐PDT with erythrosine, since they are easily accessible materials for the dental surgeon and can be applied in clinical practice.

2024-05-01·The American surgeon

The Impact of Preoperative Chlorhexidine Baths on Surgical Site Infections and Readmissions in Pediatric Patients Undergoing Laparoscopic Cholecystectomy

Article

作者: Samuels, Shenae ; Levene, Tamar ; Weiss, Michael ; Motta, Monique ; Avila, Azalia

项与盐酸氯己定相关的新闻（医药）

2024-02-01

·Science Daily

Large multicenter clinical trial finds that antiseptic containing iodine reduces surgical-site infections in patients with extremity fractures

A large multicenter clinical trial found that an antiseptic containing iodine resulted in about one-quarter fewer post-surgical infections in patients with limb fractures compared to another frequently used skin antiseptic. Researchers believe the results of the study of nearly 8,500 patients across the United States and Canada could prevent thousands of surgical-site infections each year. A large multicenter clinical trial co-led by University of Maryland School of Medicine researchers large multicenter clinical trial co-led by University of Maryland School of Medicine researchers found that an antiseptic containing iodine resulted in about one-quarter fewer post-surgical infections in patients with limb fractures compared to another frequently used skin antiseptic. The results of the study of nearly 8,500 patients across the United States and Canada were published today in the New England Journal of Medicine. The study -- which compared the two most commonly used alcohol-based solutions, one with iodine povacrylex, and the other with chlorhexidine gluconate -- may prompt changes in the type of antiseptic orthopaedic surgeons use to prepare the skin to repair fractures. Researchers saw the benefit in patients with closed, or simple fractures, where the skin remains intact, but not in compound fractures with open wounds, although they noted that using the iodine preparation was not harmful to these open-fracture patients. "Our results suggest that the use of iodine povacrylex in alcohol as a preoperative skin antiseptic could prevent surgical-site infections in thousands of patients with closed fractures each year," said co-principal investigator Gerard Slobogean, MD, MPH, an Associate Professor of Orthopaedics and Director of Clinical Research in the Department of Orthopaedics at the University of Maryland School of Medicine (UMSOM). He is also an orthopaedic trauma surgeon at the R Adams Cowley Shock Trauma Center at the University of Maryland Medical Center (UMMC). Each year, more than a million Americans suffer a broken bone in the arm, leg, or pelvis that requires surgery, and about 3 percent of these patients develop a surgical-site infection. The source of bacteria could be the patient's skin, the injury environment, or from the hospital. Although some guidelines have favored using chlorhexidine gluconate over other iodine products, there has not been a consensus on the most effective agent. Dr. Slobogean and his colleagues believe that the trial, which included 8,485 patients treated at 25 trauma centers, is the largest randomized clinical trial ever conducted to compare the two antiseptics, which allowed them to detect important differences in infection. They said that the findings may also be relevant to other surgical specialties. More than 6,700 patients who had surgery to treat a closed lower extremity or pelvic fracture and 1,700 patients who had surgery to treat an open fracture participated in the study. The R Adams Cowley Shock Trauma Center and University of Maryland Capital Region Health's (UM Capital) trauma center in Largo, Md., were among more than two dozen trauma centers to enroll patients. UMMC and UM Capital are part of the 11-hospital University of Maryland Medical System (UMMS). "The results of this well-designed study provide some long overdue clarity to orthopaedic trauma surgeons with respect to which commonly used antiseptic skin preparation is more effective when preparing for fracture surgery," said study co-author Todd Jaeblon, DO, an Associate Professor of Orthopaedics at UMSOM who treats patients at UM Capital. Of the 3,205 closed-fracture patients who received 0.7% iodine povacrylex in 74% isopropyl alcohol, 77, or 2.4 percent, developed a surgical-site infection. That compares with 108, or 3.3 percent of the 3,272 patients who received 2% chlorhexidine gluconate in 70% isopropyl alcohol. In patients with open fractures, the number of patients who developed infections was similar between the two antiseptics -- 54 patients, or 6.5 percent of 825 patients in the iodine group, and 60 patients, or 7.3% of the 826 patients in the chlorhexidine group. "Extremity fractures and the challenging surgical-site infections that result from them pose a significant health care burden on our nation," said Mark T. Gladwin, MD, who is the John Z. and Akiko K. Bowers Distinguished Professor and Dean, UMSOM, and Vice President for Medical Affairs, University of Maryland, Baltimore. "This pragmatic trial tested two widely used antiseptics, and its crossover design minimized selection bias. It also enrolled patients from 25 diverse hospitals in the U.S. and Canada, which improved the generalizability of the results; the strength of the study design could serve as a model for other researchers." The PREPARE (Pragmatic Randomized Trial Evaluating Preoperative Alcohol Skin Solutions in Fractured Extremities) trial was jointly led by UMSOM and McMaster University of Hamilton, Ontario. It was funded with $11.2 million from the Patient-Centered Outcomes Research Institute (PCORI), with additional support from the Canadian Institutes of Health Research. "This trial represents a highly successful collaboration between McMaster University, the University of Maryland School of Medicine, and 25 trauma centers across Canada and the United States," said co-principal investigator Sheila Sprague, PhD, an Associate Professor and Research Director at McMaster University. "This multidisciplinary approach allowed us to quickly and efficiently address an important clinical research question that will lead to the prevention of thousands of infections each year. Importantly, our collaborations will continue to grow to address other unanswered questions in orthopaedic trauma surgery." This is the second clinical study co-led by Dr. Slobogean and Dr. Sprague aimed at closing the gaps in the medical literature on the most effective infection-control techniques in orthopaedic surgery. In October 2022, they published the results of the Aqueous-PREP trial in The Lancet. They concluded that the choice of an aqueous antiseptic solution -- either 10% povidone-iodine or 4% chlorhexidine gluconate -- does not alter the risk of surgical-site infection for patients with an open fracture. Both Aqueous-PREP and PREPARE follow a master protocol called PREP-IT (Program of Randomized Trials to Evaluate Preoperative Antiseptic Skin Solutions in Orthopaedic Trauma) to test infection prevention techniques in trials that will provide crucial evidence to help guide surgical practices. This research was supported by the PREP-IT investigators, which includes a network of over 200 physicians, allied health care professionals, trauma patients, and clinical researchers.

临床结果临床研究

2023-12-13

·Business Wire

Ondine Successfully Raised C$4.91 Million to Support Acceleration of Its Commercial Rollout of Nasal Decolonization to Prevent Healthcare-associated Infections

VANCOUVER, Canada--( BUSINESS WIRE )--Following its successful fundraising of C$4.91 million (US$3.62), Canadian life sciences company Ondine Biomedical Inc. will continue accelerating commercialisation of its proven nasal photodisinfection technology. This cutting-edge technology replaces topical antibiotics for the prevention of healthcare-associated infections (HAIs) and kills all types of pathogens – bacteria, viruses and fungi – without causing antimicrobial resistance. The company has confirmed that it has more than doubled the number of Steriwave ® deployments in 2023 and is in discussions with more than 75 hospitals in the UK, Mexico, Spain, and Canada. The growing global focus on preventing HAIs post-surgery, coupled with the escalating challenge of antimicrobial resistance, has spurred heightened interest in Ondine’s photodisinfection technology. The deployments are in areas of major surgery, including spinal, orthopedic, and cardiovascular. The antibiotic mupirocin has been used for nasal decolonization for the prevention of HAIs since the 1980s. However, mupirocin has resistance rates of up to 81%, 2 and very poor compliance. 3 Carolyn Cross, CEO of Ondine, commented, "We have put great efforts into improving our commercial activity sales process, which has increased the speed of the average sales cycle from contact to deployment by 50%. We have appointed distributors in the UK, Spain, and Mexico and are gaining real momentum. What is particularly encouraging is that many hospitals are recommending Steriwave to other hospitals. We believe this momentum will continue to increase, and commercial sales will become more significant in 2024.” The five-minute Steriwave nasal decolonization procedure is easy to incorporate into the pre surgery procedures. It is painless and very well received by patients who are often intrigued by the process. There have been no reports of serious side effects as a result of Steriwave usage. Steriwave has been used by more than 150,000 patients, including at Vancouver General Hospital where its use has been associated with a significant reduction in HAIs across major surgeries. 4,5 As well as growing its commercial activities, the company continues to work closely with HCA – the largest hospital group in the United States – to prepare for the Phase 3 trial in circa 14 HCA hospitals as part of its Ondine’s submission to the FDA for approval. The company already has approval for Steriwave in Canada, the UK, the EU, and Mexico. Implementing nasal decolonization prior to major surgery to reduce HAIs is recommended by leading medical bodies, including the World Health Organization, 6 the Society for Healthcare Epidemiology of America (SHEA), 7 and NICE. 8 The nose is the major reservoir of pathogens and the majority of surgical site infections (SSIs) and bloodstream infections have been traced back to bacteria in the patient’s nose. 9 A patient with a surgical site infection (SSI) will, on average, spend 7 to 11 days longer in the hospital, significantly increasing costs and lengthening patients' recovery. 10 While currently focusing on nasal decolonization, Ondine’s patented photodisinfection technology will be developed to prevent and treat a wide variety of topical infections. About Ondine Biomedical Inc. Ondine Biomedical Inc. is a Canadian life science company pioneering the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications. 1 Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):417-22. doi: 10.1586/erp.09.53. PMID: 19817525; PMCID: PMC2827870. 2 Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother . 2015;70(10):2681-2692. doi:10.1093/jac/dkv169 3 Hansen D, Patzke PI, Werfel U, Benner D, Brauksiepe A, Popp W. Success of MRSA eradication in hospital routine: depends on compliance. Infection. 2007 Jun;35(4):260-4. doi: 10.1007/s15010-007-6273-y. Epub 2007 Jul 23. PMID: 17646910. 4 Bryce E, Wong T, Forrester L, Masri B, Jeske D, Barr K, Errico S, Roscoe D. Nasal photodisinfection and chlorhexidine wipes decrease surgical site infections: a historical control study and propensity analysis. J Hosp Infect. 2014 Oct;88(2):89-95. doi: 10.1016/j.jhin.2014.06.017. Epub 2014 Aug 1. Erratum in: J Hosp Infect. 2015 Sep;91(1):93. PMID: 25171975. 5 Moskven E, Banaszek D, Sayre E, Gara A, Bryce E, Wong T, Ailon T, Charest-Morin R, Dea N., Dvorak M, Fisher C, Kwon B, Paquette S, Street J. Effectiveness of prophylactic intranasal photodynamic disinfection therapy and chlorhexidine gluconate body wipes for surgical site infection prophylaxis in adult spine surgery. Can J Surg. 2023 Nov;66(6), E550–E560. https://doi-org.libproxy1.nus.edu.sg/10.1503/cjs.016922 6 World Health Organization. Global Guidelines for the Prevention of Surgical Site Infection. World Health Organization; 2016. Available at: https://www-who-int.libproxy1.nus.edu.sg/publications/i/item/9789241550475 . Accessed December 12, 2023. 7 Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67 8 National Institute for Health and Care Excellence (NICE). NICE Surgical Site Infections: Prevention and Treatment. NICE; 2019. Available at: https://www.nice.org.uk/guidance/ng125 . Accessed December 12, 2023. 9 von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001 Jan 4;344(1):11-6. doi: 10.1056/NEJM200101043440102. PMID: 11136954. 10 Seidelman JL, Mantyh CR, Anderson DJ. Surgical Site Infection Prevention: A Review. JAMA. 2023;329(3):244–252. doi:10.1001/jama.2022.24075

临床3期上市批准

2023-12-05

·GlobeNewswire-Health Care

Teleflex Awarded Peripheral Access Agreement with Premier, Inc.

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing agreement with Premier, Inc. Effective December 1st, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex’s Peripheral Access products. Premier has awarded Teleflex a national multi-source agreement for Peripherally Inserted Central Catheters (PICCs), PICC navigation equipment, and Midlines. “Teleflex strives to deliver vascular access products that are designed to benefit both clinicians and patients, while helping to protect against vascular access related complications1-7,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular. “We are pleased to continue to support Premier members with these PICC, Midline and Navigation products. Arrow™ PICCs and Midlines are available in a traditional design or with Arrowg+ard Blue Advance™ Protection Technology that’s proven effective to reduce catheter colonization by the major central line associated blood stream infection (CLABSI) causing pathogens.”2-7 Teleflex, through its Arrow™ Peripheral Access products, has recently refreshed the portfolio to help healthcare providers optimize patient outcomes, reduce catheter colonization of the major central line-associated infections (CLABSI) causing pathogens, and efficiently streamline insertion procedures1-7. The group purchasing agreement includes access to the: Arrow™ VPS Rhythm DLX™ Device capital equipment portfolio for PICC placementsArrow™ PICCs preloaded with the NaviCurve™ StyletArrow™ VPS G4™ Capital Equipment portfolio for PICC placementsTraditional Arrow™ PICCsArrowg+ard Blue Advance™ Antimicrobial/Antithrombogenic PICCsTraditional Arrow™ MidlinesArrowg+ard Blue Advance™ Antimicrobial/Antithrombogenic MidlinesArrow™ Twin Cath™ Peripheral CathetersPeripheral Access accessories Teleflex is committed to supporting vascular access specialists in their efforts to reduce vascular-related complications by offering the world's first antimicrobial and antithrombogenic PICCs and Midlines.3,7 Utilizing Arrowg+ard Blue Advance™ PICCs and Midlines guards against CLABSI-causing pathogens in areas that are clinically out of reach.3,7 This protection lasts while the line is in the patient for at least 30 days.3,7 The next-generation VPS Rhythm™ DLX Device provides real-time catheter tip location information by using the patient’s cardiac electrical activity. The device is also available with an optional integrated ultrasound featuring a Catheter-to-Vessel ratio tool that promotes standardization in vessel measurement. This device works in concert with the Arrow™ PICC preloaded with the NaviCurve™ Stylet, providing innovative tip navigation/location technologies. The VPS Rhythm™ DLX Device with TipTracker™ Technology eliminates the need for a confirmatory x-ray8, helping the clinician insert seamlessly through ultrasound vessel assessment, PICC navigation, to final tip confirmation in the lower third of the superior vena cava.1 Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. About Teleflex IncorporatedTeleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com. Teleflex is the home of Arrow™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. References1. D041679 Benchtop Stylet Advancement in a Simulated Use Anatomical Model of NaviCurve™. Product Stylet/PICC Assemblies. Bench testing may not be indicative of clinical performance. 2. In-vitro data on file 2010: AVER-004371 and AVER-004483. No correlation between in-vitro/in-vivo testing methods and clinical outcomes have currently been ascertained.3. As compared to uncoated PICCs, intravascular ovine model inoculated with Staph aureus: AVAR-000427. No correlation between in-vitro/in-vivo testing methods and clinical outcomes have currently been ascertained.4. Grau D, Clarivet B, Lotthé A, Bommart S, Parer S. Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study. Antimicrob Resist Infect Control. 2017;6:18. doi:10.1186/s13756-016-0161-0 5. Moreau N. Preventing PICC complications: whose line is it? Patient Safety Network. December 1, 2012. Accessed January 9, 2023. https://psnet.ahrq.gov/web-mm/preventing-picc-complications-whose-line-it 6. Estimating the additional hospital inpatient cost and mortality associated with selected hospital-acquired conditions. Agency for Healthcare Research and Quality. November 2017. Accessed November 9, 2022. https://www.ahrq.gov/hai/pfp/haccost2017-results.html 7. In-vitro data on file 2010: AVER-004371, AVER-004483 and AVAR-000427. No correlation between in vitro/in vivo testing methods and clinical outcomes has currently been ascertained.8. DLX-200-OPM-US: VPS Rhythm™ DLX Operator's Manual. Rx only Contraindication: Clinical assessment of the patient must be completed to ensure no contraindications exist. The Arrowg+ard Blue Advance™ PICC is contraindicated in the following areas: • Patients with known hypersensitivity to chlorhexidine• In presence of device related infections• In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained. For complete indications, contraindications, warnings, precautions, and adverse reactions, please refer to each referenced product's full package insert. Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Advance, Deknatel, LMA, NaviCurve, Pilling, QuikClot, Rüsch, TipTracker, UroLift, VPS Rhythm, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks or registered trademarks of their respective owners. © 2023 Teleflex Incorporated. All rights reserved. MC-009285 Contact:Teleflex Incorporated:Lawrence KeuschVice President, Investor Relations and Strategy Developmentinvestors.teleflex.com610-948-2836

100 项与盐酸氯己定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01345	-	-	DB00878

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCD2023	N/A	-	-	Chlorhexidine Gentle hand wash (Microshield®)	膚餘艱積繭網窪鏇顧淵(製顧廠製淵製簾鏇衊艱) = 艱醖築製襯衊蓋鬱顧餘願積鑰鹽獵餘鹹鏇鹽繭 (淵鏇製鏇夢壓糧壓餘鑰 )	-	2023-07-03
				Chlorhexidine Gentle hand wash (Gentle wash)	膚餘艱積繭網窪鏇顧淵(製顧廠製淵製簾鏇衊艱) = 襯淵窪選簾襯衊廠醖網願積鑰鹽獵餘鹹鏇鹽繭 (淵鏇製鏇夢壓糧壓餘鑰 )
DRKS00010475 (Pubmed)	N/A	脓毒症	-	0.08% octenidine wash mitts	製廠醖蓋築淵構構鏇觸(範蓋鏇觸淵鹽製鏇壓齋) = 製顧繭簾醖醖蓋範膚選衊積艱壓餘願膚鹹醖蓋 (鬱鏇觸膚壓範齋齋糧鏇 )	-	2023-06-03
NCT03442218 (Pubmed)	N/A	胎膜早破	204	Chlorhexidine solution	憲蓋範鬱鏇醖憲選齋獵(醖餘齋窪膚糧構衊廠膚) = 鏇繭窪鑰鹽觸鹽願膚艱糧壓願齋膚鹹壓壓鬱憲 (範觸鏇範齋齋廠夢簾襯 ) 更多	积极	2022-01-17
				Saline solution	憲蓋範鬱鏇醖憲選齋獵(醖餘齋窪膚糧構衊廠膚) = 夢艱網鑰蓋積憲鏇遞簾糧壓願齋膚鹹壓壓鬱憲 (範觸鏇範齋齋廠夢簾襯 ) 更多
ISRCTN14332621 (Pubmed \| Ophthalmology)	N/A	真菌性角膜炎一线	354	Topical chlorhexidine 0.2%	膚憲壓選憲淵遞齋網艱(構廠艱憲鏇廠鹽顧艱構): P-Value = 0·013	不佳	2021-12-08
				Topical natamycin 5%
NCT03382730 (Pubmed \| Intensive Care Med)	N/A	-	3,260	oral chlorhexidine (Control)	蓋築觸積衊顧鑰鹽夢齋(積遞構膚築艱糧繭築鏇) = 簾夢願夢構遞鏇襯鏇製觸獵夢願鏇網餘築積鹽 (艱簾選網鹹製積衊鏇廠 )	-	2021-10-05
				oral chlorhexidine (Intervention)	蓋築觸積衊顧鑰鹽夢齋(積遞構膚築艱糧繭築鏇) = 鏇糧鬱膚衊壓觸鬱鬱齋觸獵夢願鏇網餘築積鹽 (艱簾選網鹹製積衊鏇廠 )
NCT01079663 (CTgov)	临床2期	种植体周围炎	60	Chlorhexidine 2.5 mg (Chlorhexidine Chip (Periochip®))	膚獵衊構遞積憲衊鑰衊(繭夢顧憲積壓鹹鏇壓廠) = 鑰襯簾鏇築艱淵衊遞襯願醖築觸餘鬱襯膚糧壓 (膚襯網憲繭鹹夢窪製網, 艱製鬱淵鹹鬱蓋選齋壓 ~ 壓願網範淵構蓋壓願鬱) 更多	-	2021-06-15
				Placebo chip (Placebo Chip)	膚獵衊構遞積憲衊鑰衊(繭夢顧憲積壓鹹鏇壓廠) = 獵衊範遞膚衊憲衊窪鬱願醖築觸餘鬱襯膚糧壓 (膚襯網憲繭鹹夢窪製網, 蓋齋糧醖襯廠壓淵顧蓋 ~ 網窪蓋築網壓齋獵壓遞) 更多
NCT02252588 (CTgov)	临床2期	慢性阻塞性肺疾病	44	Placebo+Chlorhexidine (Chlorhexidine)	夢鏇鹹壓積窪網淵襯夢(築簾範窪積簾願鹽積壓) = 網構鏇簾壓繭衊積構願鹽鹹衊鏇築繭鏇鑰繭積 (蓋餘築簾壓鬱衊鬱憲膚, 獵遞積繭醖窪蓋獵觸遞 ~ 襯鹽顧繭範醖夢鹹繭鬱) 更多	-	2020-12-29
				Placebo+Chlorhexidine (Placebo)	夢鏇鹹壓積窪網淵襯夢(築簾範窪積簾願鹽積壓) = 選顧觸壓淵繭範觸齋憲鹽鹹衊鏇築繭鏇鑰繭積 (蓋餘築簾壓鬱衊鬱憲膚, 鏇窪醖夢選鑰築餘衊糧 ~ 繭糧繭窪鑰製淵齋窪艱) 更多
NCT03412734 (CTgov)	临床4期	-	94	Chlorhexidine (Chlorhexidine Group)	願鑰鑰淵膚構壓獵糧壓(淵夢鑰觸鹽鏇鑰膚範壓) = 膚鹽醖齋窪鬱顧醖襯廠鏇構憲繭鏇選餘鬱夢淵 (廠築鑰鏇糧範製繭窪齋, 獵製齋構齋廠襯淵艱糧 ~ 鹹繭構網壓餘願獵顧觸) 更多	-	2020-11-18
				Iodine (Iodine Group)	願鑰鑰淵膚構壓獵糧壓(淵夢鑰觸鹽鏇鑰膚範壓) = 構遞糧艱蓋築壓築膚製鏇構憲繭鏇選餘鬱夢淵 (廠築鑰鏇糧範製繭窪齋, 憲憲網襯網網願壓鏇願 ~ 糧構蓋醖鹽艱獵廠築簾) 更多
NCT04399161 (CTgov)	临床2/3期	龋齿	60	Chlorhexidine (Group A (Chlorhexidine Mouthrinse))	糧憲鑰糧網淵願願簾鑰(齋醖醖憲築鬱顧遞鏇構) = 衊遞蓋艱繭鹽糧襯鑰廠鬱簾壓蓋夢蓋糧範醖獵 (獵遞網襯製鬱夢窪顧鏇, 襯鏇範壓鏇齋夢繭衊艱 ~ 簾獵襯襯鹽簾膚淵鑰築) 更多	-	2020-07-22
				Xylitol (Group B (Xylitol Mouth Rinse))	糧憲鑰糧網淵願願簾鑰(齋醖醖憲築鬱顧遞鏇構) = 夢廠範夢壓壓夢繭窪鹽鬱簾壓蓋夢蓋糧範醖獵 (獵遞網襯製鬱夢窪顧鏇, 廠顧獵網獵襯觸襯獵襯 ~ 鑰鬱艱構膚網鏇繭獵膚) 更多
STRIPES (Pubmed \| Am J Obstet Gynecol)	N/A	感染	1,356	Sage 2% chlorhexidine cloths	夢窪鹽窪憲範鹹廠艱願(齋遞蓋衊遞鹽構鹹獵糧) = 壓夢鬱積餘築壓夢築襯願衊繭夢繭窪糧顧衊廠 (淵窪鹽膚觸範膚鬱範淵 )	不佳	2020-07-01
				Sage Comfort Bath fragrance-free cloths	夢窪鹽窪憲範鹹廠艱願(齋遞蓋衊遞鹽構鹹獵糧) = 鬱選糧選鹹廠繭鹽獵選願衊繭夢繭窪糧顧衊廠 (淵窪鹽膚觸範膚鬱範淵 )